Cancer Patients May Be Treated With Drugs That Provide No Benefit
Many cancer patients may be treated with drugs that were granted accelerated approval but do not provide a clinical benefit, a study suggests.
Diagnosis & Disease Information
Aggregating Data Hides Cancer Disparities Affecting Asian and NHPI Patients in the US
Aggregated data can hide disparities in cancer incidence and outcomes among Asian and Native Hawaiian/Pacific Islander patients in the US.
Benefit Seen With SBRT Before Sorafenib in Advanced HCC
SBRT prior to sorafenib improved outcomes, compared with sorafenib alone, in a phase 3 trial of patients with advanced hepatocellular carcinoma.
Combining TACE and Sorafenib Improves Survival in HCC With PVTT
The addition of transarterial chemoembolization to adjuvant sorafenib improved outcomes for patients with hepatocellular carcinoma and portal vein tumor thrombosis in a phase 2 trial.
Cell-Free DNA Fragmentome Analysis Can Be Used to Detect Hepatocellular Carcinoma
Cell-free DNA fragmentome analysis can be used to detect hepatocellular carcinoma, according to researchers.
Robotic Resection Cuts Perioperative Morbidity With Liver Cancer
Patients who underwent robotic liver resection had shorter hospital stays and were less likely to be admitted to the ICU than patients who underwent open liver resection.
SBRT Proposed as Standard Treatment Option for Advanced Hepatocellular Carcinoma
Adding stereotactic body radiation therapy to sorafenib improves survival outcomes in patients with advanced hepatocellular carcinoma, a phase 3 trial suggests.
Imjudo Plus Imfinzi Approved for Unresectable Hepatocellular Carcinoma
The FDA has approved Imjudo (tremelimumab) in combination with durvalumab for the treatment of adults with unresectable hepatocellular carcinoma.
First-Line Pembrolizumab Failed to Improve PFS, OS in Advanced HCC
Adding pembrolizumab to lenvatinib does not improve outcomes in patients with advanced hepatocellular carcinoma, results of the LEAP-002 study suggest.
Tislelizumab Deemed Noninferior to Sorafenib in Unresectable Hepatocellular Carcinoma
Final results from the RATIONALE-301 trial suggest tislelizumab is noninferior to sorafenib for first-line treatment of unresectable hepatocellular carcinoma.
- Loading...
Loading...
Next post in ESMO 2022
Loading... 
Loading...